Effect of evaluation-based optimal treatment on metabolic syndrome in schizophrenia
XI Lingyan1 JIN Guixing2▲ QIAO Jingshuang1 HUANG Xiuqin1 ZHANG Suyun1 ZHANG Qian1
1.Department of Psychiatry，Hengshui Mental Hospital, Hebei Province, Hengshui 053800, China;
2.Department of Mental Health, the First Hospital of Hebei Medical University, Hebei Province, Shijiazhuang 050031, China
Abstract：Objective To explore the effect of evaluation-based optimal treatment on metabolic syndrome (MS) in schizophrenia. Methods From March 2017 to March 2018, 120 cases with schizophrenia who diagnosed and treated in Hengshui Mental Hospital were selected. According to the random number table method, they were divided into study group and control group, with 60 cases in each group. Study group was taking Risperidone Tablets, and those with poor curative effects switched to Olanzapine. Control group was given Risperidone Tablets. Psychopathological symptoms were assessed using the negative and positive symptom scale (PANSS), and adverse drug reactions were assessed using the treatment emergent symptom scale (TESS). Fasting blood glucose (FBG), triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) levels were recorded and compared between two groups. Results There was no significant difference in scores of positive symptoms, negative symptoms, general psychopathology and PANSS between two groups before treatment (P > 0.05). The scores of positive symptoms, negative symptoms, general psychopathology and PANSS at the end of the 4th week of treatment in two groups were lower than those before treatment, and the scores of positive symptoms and PANSS in study group were lower than those in control group, with statistically significant differences (all P < 0.05). The scores of positive symptoms, negative symptoms, general psychopathology and PANSS at the end of the 8th week of treatment in two groups were lower than those before treatment and the end of the 4th week of treatment, and the scores of general psychopathology and PANSS in study group were significantly lower than those in control group, with statistically significant differences (all P < 0.05). There was no significant difference in MS detection rate between two groups at different times (P > 0.05). There was no significant difference in body mass index (BMI), FBG, systolic blood pressure (SBP), diastolic pressure (DBP) and HDL-C between two groups before treatment (P > 0.05). TG level in study group was higher than that in control group, and the difference was statistically significant (P < 0.05). FBG and SBP levels at the end of the 4th week of treatment in study group were higher than before treatment, while BMI and HDL-C levels in control group were higher than before treatment, the levels of FBG and DBP in study group were higher than those in control group, with statistically significant differences (all P < 0.05). SBP level at the end of the 8th week of treatment in study group was lower than that at the end of the 4th week of treatment, TG level was higher than that at the 4th week of treatment, and FBG level was higher than that before treatment, BMI and DBP levels in control group were higher than those before treatment, TG and HDL-C levels in study group were higher than those in control group, with statistically significant differences (all P < 0.05). Compared with the 2th weekend of treatment, TESS scores in both groups were decreased at the 4th and 8th weeks of treatment; compared with the treatment group at the end of the 4th week, both groups had lower TESS scores at the end of the 8th week, and study group was lower than control group, with statistically significant differences (all P < 0.05). Conclusion The optimal treatment model based on evaluation is used to treat schizophrenia, which has better efficacy than traditional treatment model and has similar effects on metabolic syndrome.
[1] Henderson DC，Vincenzi B，Andrea NV，et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses [J]. Lancet Psychiatry，2015，2（5）：452-464.
[2] Brown S. Excess mortality of schizophrenia. A meta-analysis [J]. Br J Psychiatry，1997，171（6）：502-508.
[3] Grundy SM，Cleeman JI，Daniels SR，et al. Metabolic Syndrome Scientific Statement by the American Heart Association and the National Heart，Lung，and Blood Institute [J]. Curr Opin Cardiol，2006，21（1）：1-6.
[4] Kahl KG. Direct and indirect effects of psychopharmacological treatment on the cardiovascular system [J]. Horm Mol Biol Clin Investig，2018，36（1）.
[5] De Hert M，Detraux J，van Winkel R，et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs [J]. Nat Rev Endocrinol，2011，8（2）：114-126.
[6] Raben AT，Marshe VS，Chintoh A，et al. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits：A Systematic Review and Implications for Treatment [J]. Front Neurosci，2018，11：741.
[7] Osborn D，Burton A，Walters K，et al. Primary care management of cardiovascular risk for people with severe mental illnesses：the Primrose research programme including cluster RCT [J]. Southampton（UK）：NIHR Journals Library，2019.
[8] Kane JM，Leucht S，Carpenter D，et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders [J]. J Clin Psychiatry，2003，64（12）：5-19.
[9] Koro CE，Fedder DO，L′Italien GJ，et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia：population based nested case-control study [J]. BMJ，2002，325（7358）：243.
[10] Roehr B. American Psychiatric Association explains DSM-5 [J]. BMJ，2013，346：f3591.
[11] He H，Zhou Y，Yang M，et al. Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia [J]. Shanghai Arch Psychiatry，2018，30（3）：178-187.
[12] 郗玲燕，黄秀芹，张素允，等.基于评估的治疗模式对精神分裂症患者症状和功能影响的随访研究[J].临床荟萃，2019，34（6）：530-534.
[13] 中华医学会糖尿病学会代谢综合征研究协作组.中华医学糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志，2004，12（3）：156-161.
[14] Gu Y，Peng H，Dai J，et al. Evaluation of paliperidone on social function in patients with chronic schizophrenia [J]. Gen Psychiatr，2018，31（2）：e000011.
[15] 梁英，苏允爱，黄继忠，等.抗精神病药治疗精神分裂症急性期兴奋激越症状早期反应对四周疗效的预测作用[J].中华精神科杂志，2013，46（5）：307-308.
[16] 周亚楠，翟金国，陈敏.首发精神分裂症精神病未治期对认知功能和社会功能的影响[J].中国神经精神疾病杂志，2018，44（1）：38-43.
[17] Singh R，Bansal Y，Sodhi RK，et al. Modeling of antipsychotic-induced metabolic alterations in mice：An experimental approach precluding psychosis as a predisposing factor [J]. Toxicol Appl Pharmacol，2019，378：114643.
[18] Ono S，Sugai T，Suzuki Y，et al. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia：post-hoc analysis of a Japanese nationwide survey [J]. BMC Psychiatry，2018， 18（1）：180.
[19] Lee JS，Kwon JS，Kim D，et al. Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea：A Multicenter Nationwide Cross-Sectional Study [J]. Psychiatry Investig，2017，14（1）：44.
[20] Yang L，Chen J，Li Y，et al. Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics [J]. World J Biol Psychiatry，2016，17（6）：467-474.
[21] Rizos E，Tournikioti K，Alevyzakis E，et al. Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene：A Case Report [J]. In Vivo，2015，29（5）：529-531.
[22] Bonaccorso S，Sodhi M，Li J，et al. The brain-derived neurotrophic factor（BDNF）Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia [J]. Bipolar Disord，2015，17（5）：528-535.
2020, Vol. 17 
京公网安备 11010502046598号